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Invited Review – A 5-year update on epigenome-wide association studies of DNA modifications in
Alzheimer’s disease: progress, practicalities and promise
In late 2014, the first epigenome-wide association stud-
ies of DNA modifications in Alzheimer’s disease brain
samples were published. Over the last 5 years, further
studies have been reported in the field and have high-
lighted consistent and robust alterations in DNA modifi-
cations in AD cortex. However, there are some caveats
associated with the majority of studies undertaken to
date; for example, they are predominantly restricted to
profiling a limited number of loci, are principally focused
on DNA methylation, are performed on bulk tissue at
the end stage of disease and are restricted to nominating
associations rather than demonstrating causal rela-
tionships. Consequently, the downstream interpreta-
tion of these studies is limited. Owing to recent
advances in state-of-the-art cell profiling techniques,
long-read genomic technologies and genetic engineer-
ing methodologies, identifying cell-type-specific causal
epigenetic changes is becoming feasible. This review
seeks to provide an overview of the last 5 years of
epigenomic studies of DNA modifications in Alzhei-
mer’s disease brain samples and propose new avenues
for future research.
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Alzheimer’s disease: A global epidemic
Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disorder that accounts for around two-thirds of
dementia incidence and is characterized by memory loss,
difficulties with language and problem-solving and a
reduction in cognition [2,3]. In 2015, dementia affected
46.8 million people globally, with this figure projected to
exceed 74.7 million by 2030, and associated costs pre-
dicted to reach $2 trillion per year [5]. Pathologically,
AD is distinguished by the presence of extracellular
amyloid b (Ab) plaques and intraneuronal neurofibril-
lary tangles (NFT) formed from hyperphosphorylated tau
protein [7]. The characteristic spread of NFTs through
the brain has been well documented and is described by
Braak staging [9]. Other hallmarks of the disease include
reduced synaptic capacity [10], neuronal cell loss [12]
and the activation of glial cells [14]. Clinically, the
pathological features of AD are reported to start years
before the appearance of symptoms, with the preclinical
lag from initial Ab deposition suggested to be at least
15 years [17]. This delay in symptom onset, combined
with a current lack of disease-modifying treatments and
the predicted increase in disease incidence highlights the
urgent need for further research identifying novel disease
mechanisms.
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The genomic era of AD
Defining the etiology of AD has proven more elusive
than the characterization of the pathological and clini-
cal features. Large-scale twin studies in AD have
revealed a high rate of heritability (58%–79% [18]),
and thus, over the last two decades, genomic studies
have been at the forefront of the AD research field.
Although it is well established that autosomal domi-
nant mutations in genes that are part of the Ab pro-
duction pathway, such as amyloid precursor protein
(APP) and the presenilin genes (PSEN1, PSEN2), result
in familial AD (FAD) [19], which is typically early
onset (EOAD), this only accounts for 1–6% of diagnoses
[21]. In the case of sporadic AD, determining the
genetic contribution to AD aetiology was first explored
through genome-wide association studies (GWAS),
which in recent years have been combined into meta-
analyses. To date, the largest two such studies were
published only last year [22,23]; Kunkle and colleagues
nominated 25 risk variants in ~ 95,000 individuals,
whilst Jansen et al. identified 29 risk loci in a study
exceeding 450,000 individuals, as they included an
AD-by-proxy phenotype. Across all studies, the gene
that confers the greatest risk for disease still remains
the APOE gene, which was first reported over 20 years
ago; a single copy of the e4 allele confers a two- to
threefold higher risk, which rises to 12-fold in individu-
als with two alleles [25]. In recent years, it has been
shown that AD has a considerable polygenic compo-
nent [28], whereby many common variants of small
effect size contribute to the heritable risk. The summa-
tive effect of all the known, and indeed yet to be identi-
fied, common variants is approximately 33%, including
APOE e4 [29]. This has led to the development of poly-
genic risk scores (PRS) for AD, that being a composite
score of the genetic loading for disease. Although
reports vary, Escott-Price et al. [28] reported a predic-
tion accuracy of 78.2% when the PRS, APOE genotype,
age and sex were used as predictors. Exome or whole
genome sequencing projects have also nominated a
handful of loci with modest effect sizes; however, these
are relatively rare variants [30]. Interestingly, recent
work has highlighted an increasing number of somatic
single nucleotide variations (SNVs) in AD brain with
age. These mutations were enriched in genes in path-
ways known to contribute to the hyperphosphorylation
of tau [31]. Therefore, although genomic studies in AD
have given considerable insight into disease etiology, a
large proportion of disease risk remains unaccounted,
suggesting that other molecular processes may con-
tribute to the burden of disease.
Moving to the next dimension: genome-
scale studies of DNA modifications in AD
In recent years, focus has shifted onto the potential
contribution of epigenetic mechanisms to AD etiology.
Epigenetic mechanisms principally act through DNA
and histone protein chemical modifications, thereby
altering chromatin structure, to regulate gene expres-
sion in a reversible manner without altering the DNA
sequence (Figure 1) [32]. In addition, noncoding miR-
NAs offer another level of epigenetic control by post-
transcriptionally repressing gene expression (33). These
processes are discussed in further detail in Box 1. DNA
modifications, namely DNA methylation, are the most
studied epigenetic modification in the context of AD
and are the focus of this review.
Exploring the role of epigenetic processes in AD is by
no means recent, with initial empirical studies dating
back over 20 years. However, these were largely lim-
ited to profiling candidate genes, or assessing global
DNA modifications in small numbers of samples (as
reviewed in [34]). It was only owing to more recent
advances in genomic technology that 5 years ago, the
first epigenome-wide association studies (EWAS) of
DNA modifications were published, which used the Illu-
mina Infinium Methylation 450 K BeadChip Array
(450 K array) [35,36], with more studies appearing on
a year-by-year basis (Figure 2). Those first large-scale
EWAS were illuminating as although different cohorts,
tissues and sample sizes were used in the two studies, a
number of differentially methylated positions (DMPs)
were common to both studies including ANK1, CDH23,
RHBDF2 and RPL13 [37]. The Lunnon et al. study rep-
resented a cross-tissue analysis of DNA modifications
associated with Braak stage, as a measure of disease
severity, in ~ 120 individuals utilizing three cortical
brain regions (entorhinal cortex, superior temporal
gyrus and prefrontal cortex) in addition to cerebellum
and premortem blood [35]. They particularly focussed
on the ANK1 gene, demonstrating consistent hyperme-
thylation across the cortex, with no association in the
cerebellum or blood. Interestingly, the two ANK1 DMPs
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identified were shown to be consistently differentially
methylated in AD cortex in three independent data
sets, including one that used an alternative technology
(pyrosequencing) to examine an extended region of the
gene. The study by De Jager and colleagues only pro-
filed the prefrontal cortex but leveraged on the power
from >700 individuals to identify 71 plaque-associated
DMPs, of which 12 were validated in the Lunnon data
set [36]. The study highlighted in particular seven dif-
ferentially methylated loci (ANK1, CDH23, DIP2A,
RHBDF2, RPL13, SERPINF1, SERPINF2) as they also
showed altered gene expression. One of the 12
validated DMPs in this study was shown to reside in
the HOXA gene cluster. More recently, another EWAS,
which leveraged on the validation data from the Lun-
non et al. data set, highlighted a 48 kb region within
this gene, consisting of 208 probes that showed hyper-
methylation in AD prefrontal cortex [38]. The study
initially identified 10 genome-wide significant DMPs in
the PFC in ~ 150 donors that were robustly associated
with Braak stage, including one probe in the HOXA3
gene. A subsequent analysis to identify differentially
methylated regions (DMRs) consisting of multiple
neighbouring probes identified six closely located DMRs
Figure 1. An overview of different epigenetic mechanisms regulating gene expression. (A) The regulation of chromatin structure
through post-translational modifications to histone proteins, including acetylation, methylation, sumoylation, ubiquitylation,
citrullination and ADP-ribosylation. (B) The addition of chemical tags to cytosine usually in the context of a CpG dinucleotide, resulting
commonly in DNA methylation (5mC), as well as its derivatives 5hmC, 5fC and 5caC. (C) The regulation of transcription via small RNA
molecules, such as microRNAs.
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within the HOXA gene region, which upon further
inspection showed an extended region of disease-associ-
ated hypermethylation spanning >48 kb[38]. Further
EWAS using the same technology and principles have
provided additional evidence for DNA methylomic alter-
ations in AD; Watson and colleagues identified 479
diagnosis-associated DMRs by profiling the superior
temporal gyrus in 34 control and 34 AD samples.
These regions were enriched for genes involved in neu-
ronal function and development, and a subset of the
DMRs were independently associated with aging [39].
A study by Mano et al. [40] attempted to address the
issue of tissue heterogeneity by profiling the neuron-
specific DNA methylome of post-mortem brain samples
(inferior temporal gyrus) from 30 AD patients and 30
age-matched normal controls. They identified eight
DMRs consisting of 36 statistically significant probes.
They highlighted that protein levels of BRCA1 (their
most significant DMR) were increased in the cytoplasm
of neuronal cells in AD brains. A more recent study by
Gasparoni et al. [41] also looked to address the issue of
tissue heterogeneity, this time by profiling both bulk
Box 1
Overview of epigenetic mechanisms
DNA modifications
DNA methylation is the most stable and best characterized epigenetic mechanism, which occurs when DNA
methyltransferases (DNMTs) transfer a methyl group to a cytosine residue, usually in a CpG dinucleotide, form-
ing 5-methylcytosine (5mC) [1]. Traditionally, this process was thought to result in transcriptional silencing, by
blocking the binding of transcription factors [4] or recruiting methyl-binding proteins, which in turn recruit
transcriptional repressing complexes that remodel chromatin structure [6]. However, recent evidence suggests
that the relationship between DNA methylation and gene expression is more complex and context dependent;
gene body methylation has been reported to correlate with increased gene expression (8), whilst intragenic
methylation has been shown to modulate alternative splicing [11]. Although 5mC is the most studied DNA mod-
ification, other cytosine modifications have been reported in recent years; 5-hydroxymethylcytosine (5hmC), 5-
formylcytosine (5fC) and 5-carboxylcytosine (5caC) were originally thought to be intermediates in the demethy-
lation pathway. However, 5hmC in particular has been increasingly studied as an independent epigenetic mark
in the context of neurobiological phenotypes owing to its higher levels in the brain [13] and enrichment in neu-
rons [15] and genes encoding synaptic proteins [16].
Histone modifications
Chromatin compaction and therefore transcriptional ability is regulated by conformational changes to histone
proteins, including modifications such as methylation, phosphorylation, acetylation, ubiquitination, sumoylation
and adenosine diphosphate-ribosylation as well as other post-translational modifications to the amino acids that
make up histone protein structure [20]. These histone ‘tail’ modifications regulate the level of condensed state
chromatin (heterochromatin) and relaxed chromatin (euchromatin) denying or allowing access to transcription
start sites (TSS) and promotor regions within the DNA to transcription factors and other necessary cellular
machinery required for transcription. Acetylation and methylation are the most widely studied histone modifica-
tions. Histone acetylation appears to be a ubiquitous marker of gene expression (24). The second most studied
histone modification is methylation, which has differing effects on gene transcription based on which amino acid
is methylated and the number of methylation groups per amino acid.
MicroRNAs
Micro-RNAs (miRNAs) play a critical role in gene regulation. Currently, 2,654 mature human miRNAs are listed
in the latest release [22] of miRBase [26]. miRNAs are small (19–26 nucleotide) RNAs that regulate gene
expression post-transcriptionally by binding to their target mRNAs and inhibiting translation or by cleaving
them [27]. There is considerable promiscuity in miRNAs, with multiple predicted targets for a given miRNA.
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Figure 2. A timeline depicting the progress of epigenome-wide association studies of DNA modifications in AD brain that have taken
place over the last 5 years. Studies of bulk tissue are shown in blue, whilst those studies that have focused on cell populations are shown
in green.
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tissue (matched temporal cortex and frontal cortex
from 65 donors with varying degrees of AD pathology)
and sorted neuronal and non-neuronal (glia) nuclei
from the occipital cortex in 31 independent donors. No
loci reached genome-wide significance in the bulk tis-
sue, and furthermore, their top ranked loci showed no
overlap with the study by Lunnon et al. [35]. Interest-
ingly however, by performing methylomic profiling
independently in neuronal and glia cells, they were
able to identify significant Braak-associated DMPs,
demonstrating that disease-associated methylation
changes in HOXA3 and ANK1 correspond to specific
changes in neurons and glia respectively [41].
One caveat of all of the aforementioned EWAS of DNA
methylation in AD is that they have been performed on
bisulfite-treated DNA, which is unable to distinguish
between two different DNA modifications (5-methylcy-
tosine [5mC] and 5-hydroxymethylcytosine [5hmC]) (see
Box 1) and, as such, the studies are actually reporting a
sum of both modifications. A recent adaptation to the
way the DNA is processed means it is possible to sepa-
rately quantify 5mC and 5hmC. Smith and colleagues
used this method in conjunction with the 450 K array
in 96 entorhinal cortex samples to nominate a number
of differentially hydroxymethylated positions (DHPs).
One particular highlight of the study was the finding that
previous reports of disease-associated ANK1 DNA hyper-
methylation were, in fact, underestimates as it was con-
founded by DNA hypohydroxymethylation [42]. More
recently, Lardenoije et al. also used the same approach to
quantify DNA methylation and hydroxymethylation in
the middle temporal gyrus of 45 AD and 35 control
donors. In addition to exploring alterations in 5hmC,
they highlighted a DMR in the OXT gene consisting of 10
neighbouring CpG sites, which was hypomethylated in
AD. Interestingly, the authors also reported significant
DNA methylation changes in blood associated with con-
version to AD dementia in this same genomic region in a
separate preclinical cohort of 42 individuals [43]. Two
other studies that have been published to date have also
explored 5hmC levels in AD brain samples but using
alternative technologies. Zhao and colleagues [44] used
a selective chemical labelling technique to enrich for
5hmC, and then sequenced the captured libraries from a
cohort of 30 individuals with either no dementia, mild
cognitive impairment (MCI) or AD. They nominated 517
plaque-associated and 60 NFT-associated differentially
hydroxymethylated regions (DhMRs) and showed that
5hmC is enriched in genes with neurobiological func-
tions. Although promising, the study did feature low
sequencing resolution, so it was unable to completely
distinguish between 5mC and 5hmC [44]. Another study
published that year utilized reduced representation
hydroxymethylation profiling (RRHP) to analyse 5hmC
levels in the hippocampus of three AD cases and two
age-matched controls. This showed an enrichment in a
number of relevant cellular pathways [45]. The key
advantage of this study is that this technology allowed
profiling of 5hmC at >2 million genomic locations, which
represents >4 times more coverage than the 450K array;
however, given that AD is a very heterogeneous disease,
the very small sample size limits the utility of the data.
One striking observation of all AD DNA methylation
EWAS performed to date is the considerable overlap in
loci nominated across studies. This was particularly evi-
dent in a recent AD EWAS meta-analysis, which com-
bined data from six independent AD cortical EWAS
totalling >1,400 unique donors, many with multiple
brain regions available [46]. The study identified a
number of loci that showed significant differential
methylation across the cortex. These loci showed a sim-
ilar pattern of methylation change across all cohorts
and cortical tissues and were validated in additional
independent cohorts (Figure 3).
Profiling of heterogeneous tissue:
Problems, practicalities and possibilities
Despite the relative infancy of epigenomic studies in
AD, the field is rapidly building momentum and there
is now considerable evidence demonstrating robust and
reproducible genome-wide changes in various epige-
netic modifications in AD. However, there are a num-
ber of caveats of the EWAS in AD undertaken to date;
for example, they are largely restricted to profiling bulk
tissue at the end stage of disease, at a specific set of
methylation sites and cannot infer causal relationships.
However, owing to recent advances in technology, it is
becoming feasible that these could be addressed in the
next wave of studies.
The issue of mixed pathologies and inconsistent
diagnostic criteria
One particularly pertinent issue when studying post-
mortem human brain tissue is that many individuals
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Figure 3. A forest plot depicting DNA modification differences between individuals with high AD pathology and no AD pathology for a
site within ANK1. ANK1 has consistently been reported to show hypermethylation in AD cortex across many independent studies of DNA
modifications. A recent meta-analysis of all available EWAS of DNA modifications included cortical data from >1,400 unique donors from
across six different cohorts for discovery, many with multiple brain regions available. The forest plot highlights that for probe
cg11823178 there is consistent hypermethylation in the six discovery cohorts across the cortex (black), specifically in the prefrontal
cortex (red), temporal gyrus (green) and entorhinal cortex (blue), which was not seen in the cerebellum (orange). In an independent
cohort of validation samples (purple), the pattern of pathology-associated hypermethylation was seen in the frontal cortex and seemed to
be driven primarily by non-neuronal cells, rather than neuronal cells. Cohorts and tissues are shown on the Y-axis, whilst effect size
(beta), representing the difference in DNA methylation between Braak stage 0 (no NFT pathology) and Braak stage VI (most severe NFT
pathology), is shown on the X-axis. Taken from Ref. [46]
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have mixed pathology. As such, stratifying ‘AD’ cases
from ‘controls’ based purely on clinical or neuropatho-
logical criteria for AD could result in the inclusion of
individuals with other co-existing neurodegenerative
conditions in both groups. Indeed, a recent study profil-
ing ANK1 DNA methylation in the cortex in various
different neurodegenerative diseases highlighted hyper-
methylation of this gene in individuals with vascular
dementia (VaD) and dementia with Lewy bodies (DLB),
only when individuals had co-existing AD pathology
[47]. One mechanism to control for this would be to
only include individuals in a study with pure ‘AD’
pathology and no other neurodegenerative conditions.
However, given that there are a limited number of such
brain samples available, this would considerably limit
the power of the study. Another option is to analyse
individuals with mixed pathologies, and then control
for this during the data analysis.
Techniques to address sample heterogeneity in AD
methylomic studies
Epigenetic modifications are, by their nature, cell-type
specific, allowing the development and programming of
specific cells that fulfil key roles in the body. In addition,
these modifications are known to be dynamic, able to
change a cell’s transcriptional profile to adapt to the cel-
lular environment. It is therefore likely that distinct dis-
ease-associated epigenetic changes will occur in different
cell types. Furthermore, it is known that there are alter-
ations in the proportion of different cell types in AD
brain, with a loss of neurons and gliosis [48]; given that
most studies to date have used bulk tissue, this therefore
poses a considerable limitation. In an attempt to circum-
vent this, most of these studies have attempted to bioin-
formatically correct for cellular proportions in EWAS
data using methods that can estimate cell proportions,
which can either be based on well-annotated reference
data sets in separated cell populations (reference-based)
or can be reference-free. Although these methods provide
reassurance that loci nominated in the EWAS are not
directly attributed to a shift in cell proportions, they are
still not able to discriminate which cell type is driving a
specific epigenetic signal, which greatly limits the inter-
pretation of findings. Aside from this, if epigenetic
changes in one cell type oppose epigenetic changes in
another cell type, then no total difference in epigenetic
levels will be seen in bulk tissue, meaning that many
important disease-associated changes may be missed
with this approach. To date, one EWAS in AD has
attempted to identify cell-specific changes; as previously
described, Gasparoni and colleagues [41] profiled DNA
methylation using the 450 K array in fluorescence-acti-
vated cell sorted (FACS) neuronal (NeuN+ nuclei) and
non-neuronal (NeuN- nuclei) populations in post-mor-
tem occipital cortex from 31 individuals and, impor-
tantly, were able to show the cellular origin (neuronal/
non-neuronal) of many previously reported EWAS loci,
including HOXA3 (neuron) and ANK1 (glia). Although
this study has been illuminating, given the relatively
small sample numbers and the use of the occipital cortex,
a brain region affected late in disease, these results
require further replication. In addition, there are also
limitations to this approach as it based on the expression
of a single antigen (NeuN) and so it is not possible to
determine whether the non-neuronal findings originated
from microglia, astrocytes, oligodendrocytes or other cell
types. Looking to the future, a wider range of antibodies
is required, which can detect nuclear proteins only
expressed in a specific cell subtype and that work effi-
ciently in frozen post-mortem tissue.
Aside from FACS, laser capture microdissection
(LCM) is another methodology that offers potential for
identifying cell-type-specific epigenetic changes in AD.
This technique also has some key advantages over
FACS as it allows the isolation of particular cell types
within certain structures of the brain. Furthermore, in
the context of AD, LCM would allow the isolation and
comparison between NFT-bearing neurons and unbur-
dened neurons within the same sample, which could
allow the identification of epigenetic changes prior to
the presence of pathology within a cell. LCM has suc-
cessfully been used in one AD EWAS to date; Hernan-
dez et al. [49] isolated pyramidal layer cells in 32
frontal cortex post-mortem brain samples, including 18
AD donors, before profiling on the 450 K array and
highlighted differential methylation in several previ-
ously nominated loci, including HOXA3 and BIN1, in
addition to demonstrating an enrichment of genes
associated with oxidative stress and synapsis. However,
this study was limited to a small sample number and
just explored this single population of cells. As LCM is
more labour intensive than FACS and yields of DNA
are usually lower, this means it is currently not suit-
able for large cohort studies exploring different cell
types.
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Improvements in methodologies to allow unbiased
DNA modification profiling
The majority of EWAS of DNA methylation to date
have been undertaken using the 450 K array. How-
ever, one issue with this approach is the limited num-
ber of methylation sites that are profiled (485, 577).
Although its successor, the EPIC array, provides nearly
twice the coverage (>850,000 sites), this array like its
predecessor is mainly focussed on cytosine methylation
predominantly in CpG dinucleotides. Other methodolo-
gies with wider coverage that are available and could
be applied for AD EWAS include whole genome bisulfite
sequencing (WGBS), where all DNA is sequenced, and
reduced representation bisulfite sequencing (RRBS),
where CG-rich regions of the genome are enriched and
sequenced. These techniques have largely not been
used in human AD EWAS due to the availability of the
450 K/EPIC arrays; however, they are being applied in
animal models that do not have the luxury of a cost-ef-
fective microarray platform being available for profiling
DNA methylation at present. Recent adaptations to
these sequencing methodologies mean that single-cell
(sc) WGBS and scRRBS protocols, amongst others, have
been developed and are being applied in other fields
(for a review of technologies, please see [50]). The abil-
ity to profile epigenetic variation at the level of the sin-
gle cell holds particular promise for a breakthrough in
our understanding of epigenetic processes in AD.
One issue with bisulfite-based methods is that this has
been shown to introduce sequencing bias [51]. Recent
developments in third-generation (long-read) sequencing
technology are also providing new avenues for epige-
netic research. Aside from their ability to sequence con-
siderably longer read lengths than next-generation
(short-read) methodologies [52], there are a number of
other key advantages to these technologies; they are able
to profile native DNA, meaning there is no potential PCR
bias and that it is possible to simultaneously perform
genetic and epigenetic analysis, including a range of
DNA modifications, including those to other bases
[53,54]. As previously described, a number of recent
EWAS have used bisulfite treatment and oxidative bisul-
fite treatment of DNA in parallel prior to analysis via
sequencing or on the 450 K array to quantify 5mC and
5hmC independently. However, these methods do not
quantify other cytosine modifications, namely 5-formyl-
cytosine (5fC) and 5-carboxylcytosine (5caC) (see
Box 1), where their functional relevance is controversial
as they are known to be very lowly expressed in brain
tissue [55]. Aside from long-read third-generation
sequencing, methylase-assisted bisulfite sequencing
(MAB-seq) is another method that allows base resolution
mapping of 5fC and 5caC, by enzymatically converting
unmodified cytosine to 5mC [56]. A recent study used
this technique alongside oxidative bisulfite sequencing in
induced pluripotent stem cells (iPSCs) models of AD to
allow the simultaneous quantification of four cytosine
states (5mC, 5hmC, 5fC/5caC and unmodified cytosine)
[57]. They identified different DNA modification signa-
tures of neuronal differentiation and also explored these
in three post-mortem brain samples (1 control, 2 AD) as
well as validating the 5mC profile from a previously pub-
lished EWAS of AD [36]. There is also the possibility that
this technology can be applied to study 5fC and 5caC at
the level of the single cell [58].
Establishing epigenetic causality and time course of
changes by applying novel methodologies
Possibly the most limiting factor in interpreting epige-
netic associations with disease outcomes is the question
of whether nominated loci are causal or are secondary to
the disease. In recent years, computational approaches,
such as two-step Mendelian randomization, have been
used in the context of other phenotypes to address this
issue [59]. In this approach, a genetic proxy for DNA
methylation is used to interrogate the causal relationship
between DNA methylation and outcome. However, the
approach itself has some limitations, for example, it is
only feasible if a genetic proxy can be identified and large
sample numbers are required [60].
Experimentally, genetic engineering techniques could
be utilized to investigate epigenetic causality. The clus-
tered regularly interspersed short palindromic repeats
(CRISPR) system uses RNA-guided Cas9 nucleases and
is mainly used to introduce DNA breaks which can be
repaired through homologous recombination, inser-
tion–deletion (indel) mutations or with a vector carry-
ing a desired mutation [61]. Recent modifications of
this technology have allowed the alteration of DNA
methylation at a selected locus, by using a Cas9 pro-
tein that is fused to the enzymatic domains of the DNA
methyltransferase (DMNT) or ten-eleven translocation
(TET) enzymes, which can then add or remove methyl
groups at a specific locus, respectively [62]. This would
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allow target-specific epigenetic editing, and by measur-
ing the downstream molecular and cellular conse-
quences, could in turn shed light on whether EWAS-
nominated loci are causal in disease. Although these
techniques could be undertaken in a commercial
human brain cell line, such as the SHSY-5Y (neuronal)
and SV40 (glial) lines, its application in induced
pluripotent stem cells (iPSCs) from patients particularly
merits investigation in the context of AD. This would
allow the study of whether iPSCs harbouring specific
genetic backgrounds (i.e. a high polygenic load for AD)
have different changes in phenotype as a result of the
epigenetic editing, compared to samples with a low
genetic load. In addition, as iPSCs can be transformed
into any cell type, it would also one to investigate
whether altering DNA methylation in different cell
types elicits distinct phenotypes, which is an important
point when considering translational potential. One
recent advance in iPSC technology is the generation of
brain organoid models, which represent 3D cultures of
multiple CNS-relevant cell types generated from iPSCs.
The use of epigenetic editing in these systems has the
distinct advantage in that multiple brain cell types are
present, and they better resemble the environment in
the brain. However, there are still caveats to this
approach, for example, their small size limits their
applicability for modelling an adult brain and they
have slow growth, adding considerable cost [63].
Epigenetic changes are specific to a particular cell
type, and thus, EWAS to identify disease mechanisms
need to be undertaken in an appropriate tissue (e.g. the
cortex), as studies in non-affected tissues (e.g. the cere-
bellum) deliver little mechanistic insight [35]. Although
some studies have explored DNA methylation profiles
in AD blood samples, the primary focus of those studies
has been on identifying biomarkers for disease, rather
than elucidating disease processes. One particular limi-
tation of human epigenetic studies is that these are
thus limited to analyses of post-mortem tissue at a sin-
gle (end-point) stage of disease, and so it is not possible
to explore the temporal pattern of methylation changes
with respect to the onset of pathology. Numerous
rodent models of AD are available; however, these have
traditionally been murine models of familial AD or
frontotemporal dementia (FTD) expressing humanized
genes bearing disease-causing mutations. Although
these allow the mapping of temporal changes in DNA
methylation with respect to pathology, they do not
allow the identification of causal epigenetic mecha-
nisms. However, a recent study has shown pathology
development and spread in a mouse model expressing
the human MAPT (tau) gene in the absence of any dis-
ease-causing mutations after it was inoculated intrac-
erebrally with tau extracts from a post-mortem AD
brain sample [64]. This represents an important step
forward in the field, as profiling epigenetic variation in
this (sporadic) model could help to identify causal epi-
genetic processes in sporadic AD.
Concluding points
Overall the study of epigenomic mechanisms in AD has
advanced considerably over the last 5 years. In an
emerging world of advanced laboratory techniques, AD
is becoming a data-rich area of research at other
molecular levels. It is particularly important that DNA
methylomic studies in AD are integrated with other
‘omic’ data sets, for example, those quantifying genetic
variation, histone modifications, miRNAs, transcription
and translation. When this can be achieved at the level
of the single cell, this will represent a particular
advancement in the field. One challenge in this respect
is in our ability to analyse and integrate large genome-
wide data sets and advances in computational methods
will be the turning point in facilitating the interpreta-
tion of epigenomic data in the context of AD.
One of the most exciting aspects of identifying dis-
ease-associated epigenetic changes is that they are
potentially reversible and so could represent viable
therapeutic targets. However, even in the genomics
field, despite numerous robust findings over the last
10–15 years, there has been very limited translation to
novel pharmacological compounds for AD. In reality,
there are currently no disease-modifying treatments for
AD and many clinical trials have been halted in recent
years as they have shown limited therapeutic benefit.
This is in part due to the considerable heterogeneity in
the disease course and the fact that treatments are
likely delivered too late due to the preclinical lag in
symptoms. In the context of drugs to target the epigen-
ome, the matter is further complicated by the issues of
causality, targeting the correct cell type and the
dynamicity of epigenetic marks. Nonetheless, epigenetic
drugs do represent considerable clinical promise for AD
and movements are being made towards developing
these treatments. The Biopharmaceutical company
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Oryzon currently has a Phase IIa clinical trial ‘Epige-
netic Therapy in Alzheimer’s disease (ETHERAL)’,
which is evaluating the safety and tolerability of
Vafidemstat, a dual lysine-specific histone demethylase,
in patients with mild-to-moderate AD [65]. At present,
no compounds are being pursued in AD clinical trials
that specifically target the DNA methylation machin-
ery. However, we hope that as a result of the robust
findings emerging from DNA methylomic studies of AD,
combined with advances in pharmaceutical technolo-
gies, this will simply be a matter of time.
Data availability statement
Data sharing not applicable to this article as no data
sets were generated or analysed during the current
study.
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